Unichem Pharmaceuticals recalled 230 bottles of Cyclobenzaprine Hydrochloride Tablets on August 27, 2025. The recall stems from a labeling mix-up with Meloxicam tablets, which could lead to serious health risks. Consumers should stop using the product immediately and contact their healthcare provider.
Labeling: Label Mix Up; Bottles of Meloxicam USP, 7.5mg, 90-count tablets (yellow in color), were labeled as Cyclobenzaprine Hydrochloride Tablets USP, 10 mg 90-count tablets (blue in color).
Consumers and healthcare providers should stop using this product immediately. Contact Unichem Pharmaceuticals USA Inc. or your healthcare provider for guidance. Notification method: Press Release
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Cyclobenzaprine Hydrochloride Tablets, USP, 10 mg, in 90-count bottles. It was manufactured by Unichem Laboratories, Ltd. and distributed nationwide in the USA.
The recall was initiated due to a labeling error that mixed up Cyclobenzaprine Hydrochloride Tablets with Meloxicam USP, 7.5 mg tablets. This mix-up poses a risk of patients receiving the wrong medication, which could lead to adverse health effects.
As of the recall date, no injuries have been reported. However, the potential for misuse of the medication due to labeling confusion remains a serious concern.
Consumers should stop using the recalled tablets immediately. Contact Unichem Pharmaceuticals USA Inc. or your healthcare provider for further guidance and information on returning the product.
For further assistance, consumers can reach Unichem Pharmaceuticals at their official website or by calling customer service.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.